GDF2 and pulmonary arterial hypertension: Although the rat MCT model performed as expected, as evident by the control and imatinib responses, there were no physiologically meaningful changes with WT BMP9 to improve the MCT PAH phenotype despite clear TE at 100 μg/kg with WT BMP9.